1. Home
  2. STCN vs BCAB Comparison

STCN vs BCAB Comparison

Compare STCN & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STCN
  • BCAB
  • Stock Information
  • Founded
  • STCN 1986
  • BCAB 2007
  • Country
  • STCN United States
  • BCAB United States
  • Employees
  • STCN N/A
  • BCAB N/A
  • Industry
  • STCN Advertising
  • BCAB Medicinal Chemicals and Botanical Products
  • Sector
  • STCN Consumer Discretionary
  • BCAB Health Care
  • Exchange
  • STCN Nasdaq
  • BCAB Nasdaq
  • Market Cap
  • STCN 63.4M
  • BCAB 96.2M
  • IPO Year
  • STCN 1994
  • BCAB 2020
  • Fundamental
  • Price
  • STCN $10.40
  • BCAB $2.08
  • Analyst Decision
  • STCN
  • BCAB Strong Buy
  • Analyst Count
  • STCN 0
  • BCAB 2
  • Target Price
  • STCN N/A
  • BCAB $6.00
  • AVG Volume (30 Days)
  • STCN 11.9K
  • BCAB 1.6M
  • Earning Date
  • STCN 12-12-2024
  • BCAB 11-08-2024
  • Dividend Yield
  • STCN N/A
  • BCAB N/A
  • EPS Growth
  • STCN 203.29
  • BCAB N/A
  • EPS
  • STCN 3.17
  • BCAB N/A
  • Revenue
  • STCN $169,044,000.00
  • BCAB N/A
  • Revenue This Year
  • STCN N/A
  • BCAB N/A
  • Revenue Next Year
  • STCN N/A
  • BCAB N/A
  • P/E Ratio
  • STCN $3.19
  • BCAB N/A
  • Revenue Growth
  • STCN N/A
  • BCAB N/A
  • 52 Week Low
  • STCN $7.36
  • BCAB $1.14
  • 52 Week High
  • STCN $13.00
  • BCAB $4.02
  • Technical
  • Relative Strength Index (RSI)
  • STCN 57.19
  • BCAB 55.80
  • Support Level
  • STCN $9.90
  • BCAB $1.87
  • Resistance Level
  • STCN $10.29
  • BCAB $2.13
  • Average True Range (ATR)
  • STCN 0.39
  • BCAB 0.12
  • MACD
  • STCN 0.11
  • BCAB 0.00
  • Stochastic Oscillator
  • STCN 100.00
  • BCAB 68.90

About STCN Steel Connect Inc.

Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain. It generates maximum revenue from the Direct Marketing segment. Geographically, it derives a majority of revenue from the United States and also has a presence in China; Netherlands, and others. The company serves clients in various industries including consumer electronics, communications, computing, software, storage, and retail industries.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Share on Social Networks: